GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.

Gonzalez F, Reid MW, Garcia JF, Raymond JK, Chao LC

Journal of pediatric endocrinology & metabolism : JPEM8 Dec 2025Cited by 2 (Europe PMC)

PMID41353583DOI10.1515/jpem-2025-0568PepBankPUB-41353583

Publisher page PubMedAsk about this study

Summary

ObjectivesYouth with type 1 diabetes (T1D) and obesity face challenges in achieving optimal glycemic control and experience higher risk for long-term complications. While glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown weight and glycemic benefits in adults with type 1 diabetes, data in pediatric populations are scarce. We report here changes in glycemia, weight, and insulin doses in youth with T1D and obesity prescribed GLP-1RA.MethodsWe conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024. Data collected included HbA_1c, body weight, BMI, total daily insulin dose (TDD), and continuous glucose monitoring (CGM) metrics. Linear mixed effects models assessed changes over time, adjusting for age and gender.ResultsAmong 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04). CGM time-in-range increased by +7.96 % (p=0.08), and time above range (180-250 mg/dL) decreased by -3.04 % (p=0.06). TDD among pump users declined by -21.42 % (p=0.002). After approximately 16 months, HbA_1c decreased by -0.81 % (p=0.04). Side effects were mainly gastrointestinal and transient.ConclusionsThis first longitudinal report of GLP-1RA use in youth with T1D and obesity shows clinically meaningful improvements in weight, glycemia, and insulin requirements, supporting the potential role of GLP-1RA as adjunct therapy. Larger prospective studies are needed to guide clinical practice.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study24

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone24

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower weight at 12 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower weight at 12 months.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−9.49 kg
12 months
Source sentences
Summary
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4135358301
02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower weight at 12 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower weight at 12 months.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−9.49 kg
12 months
Source sentences
Summary
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4135358302
03HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower weight at 12 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower weight at 12 months.
Peptide
Tirzepatide
Outcome
DecreaseBody weight
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−9.49 kg
12 months
Source sentences
Summary
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4135358303
04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower BMI at 12 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower body mass index at 12 months.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change
−3.69 kg/m2
12 months
Source sentences
Summary
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4135358304
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower BMI at 12 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower body mass index at 12 months.
Peptide
Semaglutide
Outcome
DecreaseBody mass index
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change
−3.69 kg/m2
12 months
Source sentences
Summary
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4135358305
06HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower BMI at 12 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower body mass index at 12 months.
Peptide
Tirzepatide
Outcome
DecreaseBody mass index
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
BMI change
−3.69 kg/m2
12 months
Source sentences
Summary
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4135358306
07HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower BMI z-score at 12 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower body mass index z-score at 12 months.
Peptide
Liraglutide
Outcome
DecreaseBody mass index z-score
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
BMI z-score change
−0.3
12 months
Source sentences
Summary
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4135358307
08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower BMI z-score at 12 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower body mass index z-score at 12 months.
Peptide
Semaglutide
Outcome
DecreaseBody mass index z-score
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
BMI z-score change
−0.3
12 months
Source sentences
Summary
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4135358308
09HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower BMI z-score at 12 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower body mass index z-score at 12 months.
Peptide
Tirzepatide
Outcome
DecreaseBody mass index z-score
Study
n = 24
Outcome group
Body weight · Metabolic and weight
Measurements
BMI z-score change
−0.3
12 months
Source sentences
Summary
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4135358309
10HumanNot a test of Liraglutide aloneObservational studySafety outcome
In youth with type 1 diabetes and obesity using pooled GLP-1 receptor agonists, gastrointestinal side effects were reported and were mostly transient.
In plain wordsIn youth with type 1 diabetes and obesity using pooled GLP-1 drugs, stomach side effects were mostly temporary.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal side effects
Study
n = 24
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Side effects were mainly gastrointestinal and transient.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4135358322
11HumanNot a test of Semaglutide aloneObservational studySafety outcome
In youth with type 1 diabetes and obesity using pooled GLP-1 receptor agonists, gastrointestinal side effects were reported and were mostly transient.
In plain wordsIn youth with type 1 diabetes and obesity using pooled GLP-1 drugs, stomach side effects were mostly temporary.
Peptide
Semaglutide
Outcome
Not applicableGastrointestinal side effects
Study
n = 24
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Side effects were mainly gastrointestinal and transient.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4135358323
12HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In youth with type 1 diabetes and obesity using pooled GLP-1 receptor agonists, gastrointestinal side effects were reported and were mostly transient.
In plain wordsIn youth with type 1 diabetes and obesity using pooled GLP-1 drugs, stomach side effects were mostly temporary.
Peptide
Tirzepatide
Outcome
Not applicableGastrointestinal side effects
Study
n = 24
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Side effects were mainly gastrointestinal and transient.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4135358324
13HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
Pooled GLP-1 receptor agonists including liraglutide did not significantly change continuous glucose monitoring time-in-range in youth with type 1 diabetes and obesity.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs including liraglutide did not significantly change time in glucose range.
Peptide
Liraglutide
Outcome
No significant changeContinuous glucose monitoring time-in-range
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Time-in-range change
7.96%
CGM users; P=0.08
Source sentences
Summary
CGM time-in-range increased by +7.96 % (p=0.08), and time above range (180-250 mg/dL) decreased by -3.04 % (p=0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4135358310
14HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
Pooled GLP-1 receptor agonists including semaglutide did not significantly change continuous glucose monitoring time-in-range in youth with type 1 diabetes and obesity.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs including semaglutide did not significantly change time in glucose range.
Peptide
Semaglutide
Outcome
No significant changeContinuous glucose monitoring time-in-range
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Time-in-range change
7.96%
CGM users; P=0.08
Source sentences
Summary
CGM time-in-range increased by +7.96 % (p=0.08), and time above range (180-250 mg/dL) decreased by -3.04 % (p=0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4135358311
15HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Pooled GLP-1 receptor agonists including tirzepatide did not significantly change continuous glucose monitoring time-in-range in youth with type 1 diabetes and obesity.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs including tirzepatide did not significantly change time in glucose range.
Peptide
Tirzepatide
Outcome
No significant changeContinuous glucose monitoring time-in-range
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Time-in-range change
7.96%
CGM users; P=0.08
Source sentences
Summary
CGM time-in-range increased by +7.96 % (p=0.08), and time above range (180-250 mg/dL) decreased by -3.04 % (p=0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4135358312
16HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
Pooled GLP-1 receptor agonists including liraglutide did not significantly change continuous glucose monitoring time above range in youth with type 1 diabetes and obesity.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs including liraglutide did not significantly change time above glucose range.
Peptide
Liraglutide
Outcome
No significant changeContinuous glucose monitoring time above range
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Time above range change
−3.04%
180-250 mg/dL
Source sentences
Summary
CGM time-in-range increased by +7.96 % (p=0.08), and time above range (180-250 mg/dL) decreased by -3.04 % (p=0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4135358313
17HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
Pooled GLP-1 receptor agonists including semaglutide did not significantly change continuous glucose monitoring time above range in youth with type 1 diabetes and obesity.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs including semaglutide did not significantly change time above glucose range.
Peptide
Semaglutide
Outcome
No significant changeContinuous glucose monitoring time above range
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Time above range change
−3.04%
180-250 mg/dL
Source sentences
Summary
CGM time-in-range increased by +7.96 % (p=0.08), and time above range (180-250 mg/dL) decreased by -3.04 % (p=0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4135358314
18HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Pooled GLP-1 receptor agonists including tirzepatide did not significantly change continuous glucose monitoring time above range in youth with type 1 diabetes and obesity.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs including tirzepatide did not significantly change time above glucose range.
Peptide
Tirzepatide
Outcome
No significant changeContinuous glucose monitoring time above range
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Time above range change
−3.04%
180-250 mg/dL
Source sentences
Summary
CGM time-in-range increased by +7.96 % (p=0.08), and time above range (180-250 mg/dL) decreased by -3.04 % (p=0.06).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4135358315
19HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In pump-using youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower total daily insulin dose.
In plain wordsIn pump-using youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower total daily insulin dose.
Peptide
Liraglutide
Outcome
DecreaseTotal daily insulin dose among pump users
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Total daily insulin dose change
−21.42%
pump users
Source sentences
Summary
TDD among pump users declined by -21.42 % (p=0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4135358316
20HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In pump-using youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower total daily insulin dose.
In plain wordsIn pump-using youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower total daily insulin dose.
Peptide
Semaglutide
Outcome
DecreaseTotal daily insulin dose among pump users
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Total daily insulin dose change
−21.42%
pump users
Source sentences
Summary
TDD among pump users declined by -21.42 % (p=0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4135358317
21HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In pump-using youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower total daily insulin dose.
In plain wordsIn pump-using youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower total daily insulin dose.
Peptide
Tirzepatide
Outcome
DecreaseTotal daily insulin dose among pump users
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Total daily insulin dose change
−21.42%
pump users
Source sentences
Summary
TDD among pump users declined by -21.42 % (p=0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4135358318
22HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower HbA1c at approximately 16 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower HbA1c at approximately 16 months.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−0.81%
approximately 16 months
Source sentences
Summary
After approximately 16 months, HbA_1c decreased by -0.81 % (p=0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4135358319
23HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower HbA1c at approximately 16 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower HbA1c at approximately 16 months.
Peptide
Semaglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−0.81%
approximately 16 months
Source sentences
Summary
After approximately 16 months, HbA_1c decreased by -0.81 % (p=0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4135358320
24HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In youth with type 1 diabetes and obesity, pooled GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide were associated with lower HbA1c at approximately 16 months.
In plain wordsIn youth with type 1 diabetes and obesity, pooled GLP-1 drugs were linked to lower HbA1c at approximately 16 months.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−0.81%
approximately 16 months
Source sentences
Summary
After approximately 16 months, HbA_1c decreased by -0.81 % (p=0.04).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a single-center retrospective observational study of adolescents and young adults (ages 10-20) with T1D and obesity prescribed GLP-1RA (liraglutide, exenatide, dulaglutide, semaglutide, or tirzepatide) between 2019 and 2024.
Summary · context
Among 24 patients (75 % female, 67 % public insurance, 88 % CGM users, 67 % insulin pump users), 12 months of GLP-1RA treatment led to significant reductions in weight (-9.49 kg, p2, p<0.0001), and BMI Z-score (-0.30, p=0.04).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Show in the study text Report a problemFND-4135358321

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.